Compare OMER & SWBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OMER | SWBI |
|---|---|---|
| Founded | 1994 | 1852 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Ordnance And Accessories |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 772.8M | 651.8M |
| IPO Year | 2008 | 2000 |
| Metric | OMER | SWBI |
|---|---|---|
| Price | $9.27 | $14.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $32.50 | $14.00 |
| AVG Volume (30 Days) | ★ 2.3M | 1.0M |
| Earning Date | 05-14-2026 | 06-17-2026 |
| Dividend Yield | N/A | ★ 3.37% |
| EPS Growth | ★ 98.15 | 36.67 |
| EPS | ★ 0.62 | 0.41 |
| Revenue | $29,868,000.00 | ★ $523,845,000.00 |
| Revenue This Year | N/A | $7.61 |
| Revenue Next Year | $233.22 | $3.72 |
| P/E Ratio | ★ $14.97 | $36.46 |
| Revenue Growth | N/A | ★ 10.36 |
| 52 Week Low | $3.34 | $7.73 |
| 52 Week High | $17.65 | $17.56 |
| Indicator | OMER | SWBI |
|---|---|---|
| Relative Strength Index (RSI) | 40.66 | 47.68 |
| Support Level | $9.12 | $13.83 |
| Resistance Level | $11.88 | $15.30 |
| Average True Range (ATR) | 0.92 | 0.87 |
| MACD | 0.04 | -0.04 |
| Stochastic Oscillator | 62.40 | 33.73 |
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
Smith & Wesson Brands Inc is a U.S.-based leader in firearm manufacturing. It operates under one reportable segment: Firearms, which includes firearms distribution and manufacturing services. The company manufactures handguns, long guns, sporting rifles, shooting gear, and suppressor products. The firm's brand portfolio consists of Smith and Wesson, M&P, Thompson/Center Arms, Performance Center, and Gemtech; which are used for defense, law enforcement, hunting, and sporting purposes. The company operates internationally, with the majority of income generated by the U.S. market from its handgun products.